Free Daily Podcast Summary
BioCentury This Week: Daily Summaries Delivered
by BioCentury
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 3 days ago39 min
Ep. 369 - ASCO advances, China innovation & U.S. science under threat
Revolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the detailed data for the company’s daraxonrasib, Akeso’s Harmoni-6 readout, as well as other results from the meeting. BioCentury’s analysts then argue that U.S. biotech executives and policymakers should embrace the challenges and opportunities that come with the rise of innovation in China ...
- 1 weeks ago33 min
Ep. 368 - ASCO Preview, China Policy, ADC Linkers
At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight ADCs, bispecifics and diagnostics that are broadening the field’s approach to the cancer. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss Revolution’s daraxonrasib, other readouts to watch for in pancreatic cancer and what else is on BioCentury’s radar at this year’s American Society of Clinical Oncology meeting. BioCentury’s a...
- 2 weeks ago30 min
Ep. 367 - FDA, obesity targets and the rise of DACs
Marty Makary wasn’t the only official on the outs at FDA last week in another tumultuous turn of events for the regulatory agency. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin discusses who’s in, who’s out and what’s next at FDA — and why the changes may mean more conservative decision-making at the agency in the near term. BioCentury’s analysts also discuss the new obesity targets that came to light at last week’s annual meeting of the European Congres...
- 3 weeks ago43 min
Ep. 366 - Europe's need for speed: Bio€quity takeaways
China’s speed in generating first-in-human data has catalyzed a race across the globe to reshape regulatory requirements to compete. BioCentury’s analysts, along with special guests Detlev Mennerich, head of Boehringer Ingelheim Venture Fund, and Mehdi Ainouche, partner at Jeito Capital, discussed where Europe fits in that landscape and other takeaways from the 26th annual Bio€quity Europe conference in Prague. This special episode of BioCentury This Week has been brought to you by Jeito Capi...
- 3 weeks ago30 min
Ep. 365 - Thin ice for Makary, redosing AAVs
Marty Makary’s hold on the top job at FDA is slipping, with White House leaks about President Donald Trump’s displeasure with the FDA commissioner shifting the question from whether he will be fired to when. On the latest BioCentury This Week podcast, Washington Editor Steve Usdin discusses the pressures on Makary, how long he will hold onto his post, and the leading candidates to succeed him. BioCentury’s analysts then discuss solutions to AAV’s redosing problem, which could reignite industr...
- May 5, 202632 min
Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies
UCB is the latest biopharma player to consummate a multibillion-dollar deal amid a surge in biotech M&A activity, acquiring Ken Song’s Candid Therapeutics, one of the leading T cell engager companies. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the $2 billion takeout and the opportunity in the TCE space. They also assess the drug development landscape for leukodystrophies and the market for biotech IPOs on NASDAQ, where a trio of biotechs exceeded expectation...
- Apr 28, 202630 min
Ep. 363 - New targets at AACR, biopharma deals, Kurma fund
More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the focus on new ways to enhance the immune response against solid tumors and to make existing immunotherapies more effective. On the latest BioCentury This Week podcast, BioCentury’s analysts assess the new targets identified among the thousands of abstracts at AACR, as well as emerging pan-RAS inhibiting antibody-drug conjugates. The analysts also discuss Eli...
- Apr 23, 202625 min
Ep. 362 - AACR: Data and de-risking
Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Research meeting in San Diego as biotechs unveiled their latest preclinical and first-in-human oncology data. On a special edition of the BioCentury This Week podcast, IQVIA Biotech CMO James Kyle Bryan joins BioCentury’s analysts to discuss what AACR revealed about modalities gaining traction, plus shares his perspective on de-risking clinical development and e...
About BioCentury This Week
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from BioCentury This Week in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's BioCentury This Week daily summary?
It's a free AI-powered email that summarizes new episodes of BioCentury This Week as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the BioCentury This Week podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official BioCentury This Week product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by BioCentury.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does BioCentury This Week release new episodes?
BioCentury This Week publishes weekly. Our AI generates a summary within hours of each new episode.
What topics does BioCentury This Week cover?
BioCentury This Week covers topics including Science, Business, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting BioCentury This Week summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.